uniQure licenses RNA interference technology to advance Huntington’s disease program

06-Dec-2012 - uniQure B.V. announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology in Huntington’s disease. In return, uniQure granted Benitec non-exclusive access to the Company’s AAV5 ...

Benitec strengthenss Intellectual Property Position in Gene Silencing with more patents granted in Europe and the US

05-May-2011 - Benitec Ltd announced that two further patents owned or licensed exclusively by Benitec have been granted or allowed in Europe and the US respectively.The CSIRO-owned patent EP1068311-B1 (“Methods and Means for Obtaining Modified Phenotypes”), for which Benitec is the exclusive licensee in the ...

Benitec’s Hepatitis B RNAi Program with Biomics Biotechnologies Moves to the Next Stage Following Successful Stage 1 Results

23-Feb-2011 - Benitec Limited announced that following the success of the first stage of its anti-viral program to develop an RNA interference (RNAi)-based therapy against Hepatitis B virus (HBV), conducted in collaboration with China-based Biomics Biotechnologies Co. Ltd, the companies have reached agreement ...

Strengthening and Expansion of Benitec’s Patent Position in RNAi

Graham ‘099 Patent Re-Examination Certificate Issued in the US and another Graham Patent granted in a Further European Country

21-Feb-2011 - Benitec Limited announced that the United States Patent and Trademark Office (USPTO) has indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic ...

Benitec secures further rights to HIV Therapeutic

Collaboration with City of Hope in HIV trial

30-Apr-2008 - Benitec Limited has secured further intellectual property rights that underpin its HIV/AIDS lymphoma therapeutic currently undergoing clinical trials at City of Hope in Duarte, California. The therapeutic uses RNAi technology covered by Benitec's patent portfolio. City of Hope has granted ...

Benitec appoints new CFO

27-Sep-2006 - The Board of Directors of Benitec Limited announced that the Company had appointed Paul McMahon as the new Chief Financial Officer (CFO) effective immediately. Paul is a CPA and Chartered Secretary who brings extensive financial management experience to Benitec. He holds qualifications in ...

Sigma-Aldrich Initiates RNAi Partnership Program

26-Apr-2006 - Sigma-Aldrich has announced the establishment of a worldwide RNAi Partnership Program with select academic institutions to advance functional genomics research. Scientists from participating organizations will benefit from unique access to a broad portfolio of intellectual property, early access ...

Benitec delays IND filing for HIV/AIDS therapeutic pending resolution of manufacturing result

09-Feb-2006 - Benitec Ltd. announced that the Investigational New Drug (IND) filing with the US Food & Drug Administration (FDA) for its HIV/AIDS therapeutic will be delayed. The delay is due to one aberrant result in the release tests of the clinical materials, not the drug itself. Sara M. Cunningham, Chief ...

Benitec grants Sigma-Aldrich license to RNAi patent portfolio

Sigma-Aldrich Acquires Equity Stake in Benitec

27-Oct-2005 - Benitec Ltd. and Sigma-Aldrich Corporation announced the signing of two major agreements, one in which Sigma acquires an equity stake in Benitec and one in which Benitec grants Sigma a license for the use of Benitec's RNAi technology. Benitec will receive more than US $4.5 million from the equity ...

Alnylam and Benitec Form Alliance on Fundamental Intellectual Property for RNAi Therapeutics

14-Apr-2005 - Alnylam Pharmaceuticals, Inc. and Benitec Ltd. announced a licensing agreement covering fundamental intellectual property (IP) in the field of RNA interference (RNAi). Under the agreement, Alnylam will provide Benitec and its licensees an option to non-exclusively license Alnylam-controlled IP in ...